Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D₃ and alters values of parathyroid hormone, pentosidine, and bone metabolic markers

Figures & data

Table 1 Baseline patient data

Variable	MIN (n=18)	RIS (n=17)	P-value
Age (years)	70.6±6.2	68.1±5.5	0.22
Height (cm)	150.9±5.0	150.0±4.5	0.61
Weight (kg)	49.9±8.1	49.0±7.0	0.72
Lumbar BMD (g/cm^2)	0.80±0.08	079±0.08	0.62
Hip BMD (g/cm^2)	0.70±0.08	0.69±0.09	0.89

Notes: There were no significant differences between the MIN and RIS groups. Data are presented as the mean ± standard deviation. Comparisons between the groups were performed using Welch’s t-test. There was no significant difference (P<0.05).

Abbreviations: MIN, minodronate; RIS, risedronate; BMD, bone mineral density.

Figure 1 Percent changes of 25(OH)D₃ (A), whole PTH (B), and pentosidine (C) in the MIN and RIS groups.

Notes: Error bars indicate standard error. *Significant difference (P<0.05).
Abbreviations: PTH, parathyroid hormone; MIN, minodronate; RIS, risedronate.

Table 2 Laboratory data for the MIN group before and after treatment

Variable	Before treatment	After 4 months	P-value (before vs after 4 months)	% change	P-value (% change)
25(OH)D3 (ng/mL)	21.6±1.4	18.3±1.4	<0.01*	−15.7±3.4	<0.01*
Whole PTH (pg/mL)	24.4±3.0	35.2±3.0	<0.01*	51.2±11.6	<0.01*
Pentosidine (μg/mL)	0.0317±0.0026	0.0348±0.0026	0.17	16.0±7.9	<0.05*
Urinary NTX (nmol BCE/mmol Cre)	56.5±3.2	19.8±3.2	<0.01*	−62.4±4.8	<0.01*
TRACP-5b (mU/dL)	493.0±27.6	218.0±27.6	<0.01*	−50.4±5.6	<0/01*
BAP (μg/L)	31.3±1.6	21.5±1.6	<0.01*	−30.7±4.7	<0.01*
ucOC (ng/mL)	5.6±0.8	3.3±0.8	<0.01*	−38.3±10.4	<0.01*

Notes: The 4-month values of 25(OH)D₃, whole PTH, urinary NTX, TRACP-5b, BAP, and ucOC in the MIN group were significantly different from those of pretreatment levels. Data are presented as the mean ± standard error.

* Significant difference (P<0.05).

Abbreviations: MIN, minodronate; PTH, parathyroid hormone; NTX, urinary cross-linked N-telopeptide of type I collagen; TRACP-5b, tartrate-resistant acid phosphatase; BAP, bone-specific alkaline phosphatase; ucOC, undercarboxylated osteocalcin.

Table 3 Laboratory data for the RIS group before and after treatment

Variable	Before treatment	After 4 months	P-value (before vs after 4 months)	% change	P-value (% change)
25(OH)D3 (ng/mL)	21.9±1.5	18.6±1.5	<0.01*	−13.9±3.5	<0.01*
Whole PTH (pg/mL)	22.4±3.1	24.5±3.1	0.45	11.8±12.0	0.33
Pentosidine (μg/mL)	0.0295±0.0026	0.0324±0.0026	0.20	14.3±8.1	0.09
Urinary NTX (nmol BCE/mmol Cre)	67.4±3.4	37.0±3.4	<0.01*	−37.8±4.9	<0.01*
TRACP-5b (mU/dL)	519.0±28.8	339.1±28.8	<0.01*	−32.1±5.5	<0.01*
BAP (μg/L)	27.8±1.7	22.6±1.7	<0.01*	−14.7±4.8	<0.01*
ucOC (ng/mL)	6.6±0.8	4.8±0.8	<0.01*	−29.2±10.7	0.01*

Notes: The 4-month values of 25(OH)D₃, urinary NTX, TRACP-5b, BAP, and ucOC in the RIS group were significantly different from those of pretreatment levels. Data are presented as the mean ± standard error.

* Significant difference (P<0.05).

Abbreviations: RIS, risedronate; PTH, parathyroid hormone; NTX, urinary cross-linked N-telopeptide of type I collagen; TRACP-5b, tartrate-resistant acid phosphatase; BAP, bone-specific alkaline phosphatase; ucOC, undercarboxylated osteocalcin.

Figure 2 Percent changes of urinary NTX (A), TRACP-5b (B), BAP (C), and ucOC (D) in the MIN and RIS groups.

Notes: Error bars indicate standard error. *Significant difference (P<0.05).
Abbreviations: NTX, urinary cross-linked N-telopeptide of type I collagen; TRACP-5b, tartrate-resistant acid phosphatase; BAP, bone-specific alkaline phosphatase; ucOC, undercarboxylated osteocalcin; MIN, minodronate; RIS, risedronate.